- Home
- ZYME vs DCOM Comparison
ZYME vs DCOM Comparison
Compare ZYME & DCOM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZYME | DCOM |
|---|---|---|
| Founded | 2003 | 1864 |
| Country | United States | United States |
| Employees | N/A | 902 |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | ZYME | DCOM |
|---|---|---|
| Price | $26.11 | $40.18 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 5 |
| Target Price | ★ $38.90 | $37.80 |
| AVG Volume (30 Days) | ★ 625.3K | 346.1K |
| Earning Date | 05-07-2026 | 04-23-2026 |
| Dividend Yield | N/A | ★ 2.81% |
| EPS Growth | ★ 33.33 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $105,965,000.00 | N/A |
| Revenue This Year | $183.10 | $21.40 |
| Revenue Next Year | N/A | $12.65 |
| P/E Ratio | ★ N/A | $14.81 |
| Revenue Growth | ★ 38.87 | N/A |
| 52 Week Low | $11.86 | $25.63 |
| 52 Week High | $29.75 | $41.62 |
Technical Indicators
Market Signals| Indicator | ZYME | DCOM |
|---|---|---|
| Relative Strength Index (RSI) | 63.53 | 59.83 |
| Support Level | $22.44 | $38.47 |
| Resistance Level | $26.75 | $40.76 |
| Average True Range (ATR) | 1.11 | 1.03 |
| MACD | 0.40 | 0.05 |
| Stochastic Oscillator | 84.13 | 58.41 |
Price Performance
Historical ComparisonAbout ZYME Zymeworks Inc.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
About DCOM Dime Community Bancshares Inc.
Dime Commercial Bancshares Inc is the holding company for Dime Commercial Bank, a New York State-chartered trust company with approximately $15 billion in assets and the number one deposit market share on Greater Long Island.